PressPort logo
https://www.pressport.com/int/news/pressreleases/companies-spend-heavily-on-research-and-development-for-smallpox-treatment-18660
ad

Companies spend heavily on research and development for smallpox treatment

Press release August 26, 2014 Smallpox treatment, smallpox drugs

This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages.

Smallpox was one of the world’s most dangerous killers for a very long time. In 1980, it was decided that smallpox would be eradicated form the world. All countries eventually stopped vaccination and since then no case of smallpox has been detected for 35 years. But recently it has been found that six vials of smallpox have been found in the National Institutes of Health campus in Bethesda, Maryland. Fortunately the vials were moved to an isolated and secure location.

For a long time the smallpox vaccine is the only smallpox treatment known to man to prevent the disease in an already exposed person.

This report, Smallpox - Pipeline Review, H2 2014, provides comprehensive information on the therapeutic development for smallpox, along with latest updates and key players.

Market overview

No treatment has yet been approved by the US Food and Drug Administration (FDA) for smallpox, and thus the only prevention is vaccination. Certain medications, including topical idoxuridine and cidofovir, can be applied under investigational new drug (IND) protocol for better management of the smallpox treatment. Bacterial infections of the skin on the other hand can be treated with semisynthetic penicillins or first-generation cephalosporins or even clindamycin. In some cases Ampicillin or amoxicillin can also be used.

Research to assess new antiviral agents for the treatment of smallpox is still in the research phase. Recent research suggests that the drug cidofovir (Vistide) may fight the virus. Smallpox research scientists are carrying out studies with animals to fathom the drugs capability to treat the disease.

In addition to these efforts recently, the National Institute of Allergy and Infectious Diseases (NIAID) have applied to the US Food and Drug Administration (FDA) to use the antiviral drug cidofovir for the smallpox treatment.

Key players

A lot of companies are investing in research and development of drugs to prevent the disease. The key players in the smallpox treatment market are Inovio Pharmaceuticals, Inc., Bavarian Nordic A/S, Symphogen A/S , Nanotherapeutics, Inc., CEL-SCI Corporation, SIGA Technologies, Inc., TapImmune Inc., CJ CheilJedang Corp., MacroGenics, Inc., AlphaVax, Inc., EpiVax, Inc., Chimerix, Inc., Conkwest, Inc., Inhibikase Therapeutics, Inc., and Polyrizon Ltd.

For further insights,

Visit: Companies spend heavily on research and development for smallpox treatment

About Research on Global Markets

Research on Global Markets is a leading source for market research on various sectors globally, offering premium research content from worldwide publishers of market research reports. Our database hosts premium market research content developed by global publishers. It offers premium industry research reports, company profiles and country briefs. We have a dedicated team of research professionals who can facilitate, in an unbiased manner, the process of identifying appropriate market research reports that are targeted to fulfil all your information-related requirements.

For more details on the content of each report and ordering information please contact:

Email: [email protected]

US: +1 800 986 6819

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

Subjects


Smallpox treatment, smallpox drugs


ad